Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Biocytogen and Sihuan partner to advance new therapeutics for weight loss
  • M&A / Deals

Biocytogen and Sihuan partner to advance new therapeutics for weight loss

Pharmaceutical Business Review

Under the agreement, Biocytogen's fully human antibody discovery platform will be combined with Sihuan Pharmaceutical's capabilities in drug development, manufacturing, and commercialisation.

M&A / DealsMetabolic & GLP-1Read full story

pharminent April 2, 2026 (Last updated: April 2, 2026)

Pharmaceutical Business Review

Under the agreement, Biocytogen’s fully human antibody discovery platform will be combined with Sihuan Pharmaceutical’s capabilities in drug development, manufacturing, and commercialisation.

M&A / DealsMetabolic & GLP-1Read full story

Post navigation

Previous: Threat of Trump’s pharma tariffs looms again
Next: Merck KGaA acquires JSR chromatography business

Related Stories

  • M&A / Deals

BioMarin spends up to $490m for Alesta’s bone disease candidate

pharminent August 19, 2026
  • M&A / Deals

J&J hands lymphoma bispecific CAR T back to AbelZeta

pharminent August 17, 2026
  • M&A / Deals

Novo Nordisk and AWS form AI partnership to speed drug discovery

pharminent August 17, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.